According to the latest report by IMARC Group, titled, “Vaccine Adjuvants Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027“, Offers a comprehensive analysis of the industry, which comprises insights on the global vaccine adjuvants market growth. The global vaccine adjuvants market size reached US$ 773.6 Million in 2021. Looking forward, IMARC Group expects the market to reach US$ 1,617.3 Million by 2027, exhibiting a growth rate (CAGR) of 12.82% during 2022-2027.
Vaccine adjuvants are compounds utilized for improving the biological activity and the immunogenicity of a pharmaceutical preparation intended for the immunization of humans and animals against numerous diseases. They can be administered in oral, intramuscular, intranasal, subcutaneous, and intradermal forms. They aid in improving the response of the body to vaccination, minimizing the number of vaccine doses given to patients, and reducing the amount of injected foreign material. They rely on aluminum salts, such as aluminum hydroxide, aluminum phosphate, and aluminum potassium sulfate, to protect against diseases and provide more prolonged effectiveness. They are widely used in hepatitis A, hepatitis B, diphtheria-tetanus, Haemophilus influenzae type B, and pneumococcal vaccines.
Note: We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.
Get a PDF Sample for more detailed market insights: https://www.imarcgroup.com/vaccine-adjuvants-market/requestsample
Vaccine Adjuvants Market Trends and Drivers:
The increasing prevalence of contagious infections, such as human immunodeficiency virus (HIV), acquired immune deficiency syndrome (AIDS), and human papillomavirus (HPV), represents one of the major factors positively influencing the demand for vaccine adjuvants around the world. The rising occurrence of cancer among the masses, especially the geriatric population, which is more susceptible to such medical conditions, is also strengthening the market growth. It can also be accredited to the growing consumption of alcohol and tobacco products on account of sedentary lifestyles and high-stress levels. In addition, increasing incidences of zoonotic diseases, including animal flu and tick infestation, are favoring the market growth. It can also be attributed to the emerging trend of adopting pets for companionship and consequently increasing spread of animal-borne diseases. The rising awareness about animal health is also driving the demand for vaccine adjuvants worldwide. Apart from this, the increasing number of airborne diseases on account of the growing air pollution levels is resulting in the rising utilization of vaccine adjuvants. Along with this, the growing demand for effective and safe vaccine adjuvants is creating a positive outlook for the market. Moreover, the expanding number of clinical trials by pharmaceutical companies to improve vaccines that offer long-lasting effects on immunization is contributing to the market growth. Furthermore, governments of several countries are undertaking initiatives to monitor the distribution, supply, and administration of vaccine adjuvants, which is providing a thrust to the market growth. Besides this, due to inflating income levels, there is a rise in demand for sophisticated treatment options to minimize the risk of developing allergies. Additionally, continual technological advancements in the vaccine production process, significant improvement in the healthcare infrastructure, and extensive research and development (R&D) activities in the field of biotechnology are anticipated to propel the market growth in the coming years.
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players.
- Adjuvance Tecchnologies Inc.
- Adjuvatis
- Agenus Inc.
- Brenntag SE
- Chemtrade Logistics Inc.
- CSL Limited
- Croda International Plc
- Invivogen
- Novavax Inc.
- OZ Biosciences
- Virometix AG.
Vaccine Adjuvants Market 2022-2027 Competitive Analysis and Segmentation:
The report has segmented the market based on product type, route of administration, diseases and application.
Breakup by Product Type:
- Adjuvant Emulsions
- Pathogen Components
- Particulate Adjuvants
- Combination Adjuvants
- Others
Breakup by Route of Administration:
- Oral
- Intramuscular
- Intranasal
- Subcutaneous
- Intradermal
- Others
Breakup by Diseases:
- Cancer
- Infectious Diseases
- Others
Breakup by Application:
- Research
- Commercial
Breakup by Region:
- North America
- Asia-Pacific
- Europe
- Latin America
- Middle East and Africa
Ask Customization and Browse full report with TOC & List of Figure: https://www.imarcgroup.com/vaccine-adjuvants-market
Note: We are updating our reports, if you want the report with the latest primary and secondary data (2023-2028) including industry trends, market size and competitive landscape, etc. click request free sample report, published report will be delivered to you in PDF format via email within 24 to 48 hours.
If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact us:
IMARC Group
30 N Gould St, Ste R
Sheridan, WY (Wyoming) 82801 USA
Website: https://www.imarcgroup.com
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas: – +1 631 791 1145 | Africa and Europe: – +44-702-409-7331 | Asia: +91-120-433-0800